Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of biosimilar insulin degludec + liraglutide injection versus Xultophy in Chinese adults with type 2 diabetes mellitus
CTR20250744Phase 3Completed
- Sponsor
- Tonghua Dongbao
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Tonghua Dongbao. Started Mar 2025; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20250744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250744.